The announcement of an exclusive global arrangement with a significant partner like the Serum Institute of India for the supply of Bacillus Calmette-Guerin is a positive development for ImmunityBio. This partnership likely offers the company a competitive edge in its sector, potentially improving its market position and future revenue prospects. Such strategic partnerships are often viewed positively by investors, as they can lead to enhanced product offerings and market expansion, driving the stock price up in the short term.